In the past decade, radiolabeled prostate-specific membrane antigen (PSMA) ligands for PET imaging have emerged and been recognized for their potential in detecting soft-tissue and bone metastases in PC. This evidence concerns the gene FOLH1 and pachyonychia congenita.